Investment Trusts

BioPharma Credit PLC

BPCR:LSE

BioPharma Credit PLC

Actions
  • Price (USD)0.936
  • Today's Change-0.006 / -0.64%
  • Shares traded1.79m
  • 1 Year change+7.09%
  • Beta0.2624
Data delayed at least 20 minutes, as of Mar 03 2026 16:47 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Total returns on $1000

1Y
Fund/benchmarkChange
PriceBioPharma Credit PLC (Ordinary Share)+19.89%
NAVBioPharma Credit PLC (Ordinary Share)+10.31%
Morningstar's BenchmarkNo benchmark--

Key statistics

On Tuesday, BioPharma Credit PLC (BPCR:LSE) closed at 0.936, -4.47% below its 52-week high of 0.9798, set on Jun 30, 2025.
52-week range
Today
0.80Apr 09 20250.9798Jun 30 2025
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding1.13bn
Market cap1.06bn USD
Total assets1.13bn USD
Total expense ratio--
High0.97
Low0.928
Previous close0.942
Average volume1.17m
YTD Change+2.18%
Beta0.2624
Diluted NAV (est)0.9996
Diluted NAV (last pub)1.03
Premium/Discount-6.57%
Net Gearing0.00%
Annual div (ADY)0.07
USD
Annual div yield (ADY)7.43%
Div ex-dateFeb 19 2026
Div pay-dateMar 20 2026
Data delayed at least 20 minutes, as of Mar 03 2026 16:47 GMT.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.